Celgene Endorses Presage Biosciences’ Cancer Drug Analysis Platform with Strategic Collaboration |
Abstract
|
Heather Cartwright |
|
Presidio and Boehringer Ingelheim Partner to Test All-Oral Combination for HCV Genotype-1a |
Abstract
|
Heather Cartwright |
|
AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology |
Abstract
|
Heather Cartwright |
|
Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies |
Abstract
|
Heather Cartwright |
|
Astellas Adds to Antibody-Drug Conjugate Capabilities with Ambrx Collaboration |
Abstract
|
Heather Cartwright |
|
Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator |
Abstract
|
Heather Cartwright |
|
Isis Advances Antisense Drug for Huntington’s Disease in Collaboration with Roche |
Abstract
|
Heather Cartwright |
|
Santaris Pharma Gains Another Collaborator in BMS |
Abstract
|
Heather Cartwright |
|
Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration |
Abstract
|
Heather Cartwright |
|
AstraZeneca Highlights R&D Growth Strategy via Collaborations with BIND Therapeutics and Horizon Discovery |
Abstract
|
Heather Cartwright |
|
AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis |
Abstract
|
Heather Cartwright |
|
NPS Pharmaceuticals Regains Global Rights to Two Orphan Drugs from Takeda |
Abstract
|
Heather Cartwright |
|
Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme |
Abstract
|
Heather Cartwright |
|
Dainippon Sumitomo Licenses Japanese Rights to Two Redox-Directed Drugs from Edison Pharmaceuticals |
Abstract
|
Heather Cartwright |
|
Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase |
Abstract
|
Heather Cartwright |
|
Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid |
Abstract
|
Heather Cartwright |
|
Shire Adds Phase III Ophthalmology Asset to Pipeline with SARcode Bioscience Purchase |
Abstract
|
Heather Cartwright |
|